Edition:
United States

Helix Biopharma Corp (HBP.TO)

HBP.TO on Toronto Stock Exchange

0.95CAD
25 May 2017
Change (% chg)

$-0.05 (-5.00%)
Prev Close
$1.00
Open
$0.95
Day's High
$0.95
Day's Low
$0.95
Volume
5,500
Avg. Vol
12,925
52-wk High
$2.25
52-wk Low
$0.70

Latest Key Developments (Source: Significant Developments)

Helix Biopharma says Heman Chao to become CEO
Tuesday, 7 Mar 2017 07:45am EST 

Helix Biopharma Corp : Announces strategic management changes . Dr. Sven Rohmann, CEO and chairman of company, will be stepping down from his position as chief executive officer .Heman Chao will assume position of chief executive officer.  Full Article

Helix Biopharma signs LOI with Ken Poland
Wednesday, 22 Feb 2017 07:30am EST 

Helix Biopharma Corp : Helix Biopharma Corp - signed non-binding loi with ken poland in support of European centre for cancer immunotherapy .Helix Biopharma-LOI contemplates proposed investment by Ken Poland of about $30 million.  Full Article

Helix Biopharma Corp signs non-binding letter of intent with Promab Biotechnologies to develop cell based therapies
Thursday, 22 Dec 2016 07:45am EST 

Helix Biopharma Corp : Helix Biopharma Corp announces the signing of a non-binding letter of intent with Promab Biotechnologies to develop cell based therapies .Helix Biopharma - LOI calls for both cos to complete a due diligence and establish a collaboration to develop chimeric antigen receptor t cell therapy.  Full Article

Helix Biopharma Corp accelerates escalation of l-dos47 dosing in the U.S. early-stage study
Wednesday, 30 Nov 2016 07:30am EST 

Helix Biopharma Corp - : Helix Biopharma Corp accelerates escalation of l-dos47 dosing in the U.S. Phase I study .FDA accepted accelerated escalation scheme for l-dos47 dosing in U.S. Phase I study (ldos001) up to 12μg/kg with pemetrexed/carboplatin.  Full Article

Helix Biopharma announces deal with National Research Council of Canada
Monday, 18 Jul 2016 04:10pm EDT 

Helix Biopharma Corp : Helix Biopharma announces agreement in principle with National Research Council of Canada to collaborate on various immuno-oncology initiatives . Agreement spells out framework to enable Helix to finalize master agreement with NRC to develop new therapeutics for cancer immunotherapies .Agreement allows for discussion on a potential license of antibody previously obtained from NRC under a material transfer agreement.  Full Article

Helix Biopharma posts Q3 loss per share c$0.02
Tuesday, 14 Jun 2016 05:17pm EDT 

Helix Biopharma Corp : Helix Biopharma Corp announces third quarter fiscal 2016 results .Q3 loss per share c$0.02.  Full Article

Helix BioPharma Corp announces CEO change
Tuesday, 29 Mar 2016 04:45pm EDT 

Helix BioPharma Corp:Says Zbigniew Markowski will be stepping down from his positions as Chief Executive Officer of Helix BioPharma Corp and Chairman of Helix Polska, effective March 29.Sven Rohmann succeds Sven Rohmann.  Full Article

Helix BioPharma Corp appoints Zbigniew Markowski as CEO
Tuesday, 12 Jan 2016 08:01am EST 

Helix BioPharma Corp:Says appointed Zbigniew Markowski as Chief Executive Officer, replacing Gary Littlejohn who was serving as Interim CEO.Says Yvon Bastien announced his resignation as Chairman of Board and will be replaced by Sven Rohmann.  Full Article

Helix BioPharma Corp names Gary Littlejohn interim CEO
Thursday, 29 Oct 2015 04:57pm EDT 

Helix BioPharma Corp:Appointment of Gary Littlejohn as Interim Chief Executive Officer as of November 1, 2015.  Full Article

Helix BioPharma Corp announces leadership transition
Friday, 18 Sep 2015 05:37pm EDT 

Helix BioPharma Corp:Says Robert Verhagen has resigned as President and Chief Executive Officer, effective as of November 1 and as a member of Board of Directors, effective immediately.Says Verhagen will continue to serve as CEO to assist in the Company's management transition.Says if board has not appointed CEO by Nov. 1, board intends to appoint Yvon Bastien to assume role of President, CEO on interim basis.  Full Article

More From Around the Web

BRIEF-Helix Biopharma Q2 loss per share C$0.03

* Announces fiscal second quarter 2017 results and closing of private placement

No consensus analysis data available.